1. Home
  2. MSD vs PLX Comparison

MSD vs PLX Comparison

Compare MSD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

HOLD

Current Price

$7.64

Market Cap

151.1M

Sector

Finance

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.09

Market Cap

168.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSD
PLX
Founded
1993
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
168.1M
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
MSD
PLX
Price
$7.64
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
70.2K
825.9K
Earning Date
01-01-0001
03-16-2026
Dividend Yield
11.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
N/A
$61,840,000.00
Revenue This Year
N/A
$14.29
Revenue Next Year
N/A
$16.65
P/E Ratio
N/A
$30.69
Revenue Growth
N/A
35.41
52 Week Low
$6.11
$1.32
52 Week High
$7.46
$3.10

Technical Indicators

Market Signals
Indicator
MSD
PLX
Relative Strength Index (RSI) 68.87 60.56
Support Level $7.49 $2.03
Resistance Level $7.52 $2.11
Average True Range (ATR) 0.06 0.10
MACD 0.02 0.01
Stochastic Oscillator 92.86 85.92

Price Performance

Historical Comparison
MSD
PLX

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: